Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia

February 19, 2014 updated by: Boston University

Intensive Treatment of Adolescent Panic and Agoraphobia

This study will evaluate the effectiveness of intensive cognitive behavioral therapy in treating adolescents with panic disorder with agoraphobia.

Study Overview

Detailed Description

Panic disorder (PD) in adolescents is a prevalent and chronic anxiety disorder. People with PD experience unexpected attacks of fear, along with elevated heart rate, dizziness, faintness, weakness, and increased sweating. During these panic attacks, people may feel numbness in their hands, flushed or chilled, nauseous, or pain in the chest, and they may lose touch with reality. PD can lead to substantial social impairment for adolescents, including avoidance of school, independent activities, and peer involvement. When PD progresses so far that a person avoids public places where a panic attack might occur, the person is said to have a condition known as agoraphobia. Weekly sessions of cognitive behavioral therapy (CBT) appear to be effective in treating panic disorder with agoraphobia (PDA). However, many adolescents with PDA and their families report the need for a more immediate relief from the disorder. This study will evaluate the effectiveness of intensive CBT in treating adolescents with PDA.

Participants in this single blind study will be randomly assigned to one of three conditions: intensive CBT treatment including family members, intensive CBT treatment without family members, or a waitlist control group. All participants in the intensive CBT treatment groups will undergo 8 days of intensive CBT, for a total of 6 sessions. On Days 1 through 3 of treatment, participants will attend daily, 2-hour CBT sessions. The CBT sessions will include psychoeducation about anxiety, tactics to restructure anxiety-provoking thoughts, and exposure to bodily sensations that trigger panic. On Days 4 and 5, participants will meet with a therapist to learn ways to approach previously feared situations. On Days 6 and 7, participants will continue working independently or with family members to solidify skills. On Day 8, participants will attend a final 2-hour session to consolidate skills, review the independent weekend activities, and discuss ways to apply skills to the home environment. Parents of participants in the parental involvement group will attend the last 30 minutes of sessions, complete homework assignments, learn ways to coach their children through episodes, and participate in selected exposures. After 6 weeks of waitlist, participants in the waitlist control group will receive active treatment following the same procedures as the initial active treatment. All participants will be assessed at Months 3, 6, and 12 post-treatment.

Study Type

Interventional

Enrollment (Actual)

63

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Boston University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Meets DSM-IV criteria for principal diagnosis of PD or PDA prior to treatment
  • Adolescent must be accompanied by at least one parent or caregiver
  • If on medication, there must be a 1-month stabilization period for benzodiazepines or 3-month stabilization period for SSRIs or tricyclics prior to study entry

Exclusion Criteria:

  • Positive diagnosis of schizophrenia, pervasive developmental disorder, organic brain syndrome, mental retardation, or current suicidal ideation
  • Unavailability of at least one parent or caregiver
  • Refusal of parent to accept random assignment to treatment condition
  • Refusal of parent or adolescent to accept stabilization of medication
  • Adolescent with parent who has any condition that would limit ability to understand treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
Participants will receive intensive cognitive behavioral therapy treatment without parent involvement
Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
Experimental: 2
Participants will receive intensive cognitive behavioral therapy treatment with parent involvement
Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
Placebo Comparator: 3
Waitlist control group
Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Anxiety Disorders Interview Schedule-Child and Parent Versions: Clinical Severity Rating, Agoraphobia Ratings, Panic Attack Frequency Scores, and Internal Sensation Anxiety Ratings
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Panic Disorder Severity Scale-Child Version
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment

Secondary Outcome Measures

Outcome Measure
Time Frame
Multidimensional Anxiety Scale for Children
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Childhood Anxiety Sensitivity Index
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Fear and Avoidance Hierarchy
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Children's Depression Inventory
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
The Panic Attack Record
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Subjective Symptoms Scale
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Panic and Phobia Questionnaire
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Participant Global Impression of Improvement (PGI)
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Perceptions of Treatment Questionnaire: Adolescent and Parent Versions
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Children's Perception Scale (Locus of Control Scale)
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Child Behavior Checklist (CBCL)
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Stress Index for Parents of Adolescents
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Parenting Locus of Control Scale
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Therapy Attitude Inventory
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Family Assessment Measure (FAM)
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment
Depression Anxiety and Stress Scale (DASS)
Time Frame: Measured at Months 3, 6, and 12 post-treatment
Measured at Months 3, 6, and 12 post-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Donna Pincus, PhD, Boston University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2005

Primary Completion (Actual)

March 1, 2011

Study Completion (Actual)

March 1, 2011

Study Registration Dates

First Submitted

December 17, 2007

First Submitted That Met QC Criteria

December 17, 2007

First Posted (Estimate)

December 19, 2007

Study Record Updates

Last Update Posted (Estimate)

February 20, 2014

Last Update Submitted That Met QC Criteria

February 19, 2014

Last Verified

February 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • R01MH068277 (U.S. NIH Grant/Contract)
  • DSIR 84-CTS (Division of Services and Intervention Research)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Panic Disorder

Clinical Trials on Intensive panic control treatment without parent involvement

3
Subscribe